Unknown

Dataset Information

0

Ex vivo ?-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.


ABSTRACT: We have previously shown that in vivo ?-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency (XSCID) results in sustained T cell reconstitution and sustained marking in myeloid and B cells for up to 4 years with no evidence of any serious adverse effects. The purpose of this study was to determine whether ex vivo ?-retroviral gene therapy of XSCID dogs results in a similar outcome. Eight of 12 XSCID dogs treated with an average of dose of 5.8 × 10(6) transduced CD34(+) cells/kg successfully engrafted producing normal numbers of gene-corrected CD45RA(+) (naïve) T cells. However, this was followed by a steady decrease in CD45RA(+) T cells, T cell diversity, and thymic output as measured by T cell receptor excision circles (TRECs) resulting in a T cell lymphopenia. None of the dogs survived past 11 months post treatment. At necropsy, few gene-corrected thymocytes were observed correlating with the TREC levels and one of the dogs was diagnosed with a thymic T cell lymphoma that was attributed to the gene therapy. This study highlights the outcome differences between the ex vivo and in vivo approach to ?-retroviral gene therapy and is the first to document a serious adverse event following gene therapy in a canine model of a human genetic disease.

SUBMITTER: Kennedy DR 

PROVIDER: S-EPMC3109141 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.

Kennedy Douglas R DR   Hartnett Brian J BJ   Kennedy Jeffrey S JS   Vernau William W   Moore Peter F PF   O'Malley Thomas T   Burkly Linda C LC   Henthorn Paula S PS   Felsburg Peter J PJ  

Veterinary immunology and immunopathology 20110414 1-2


We have previously shown that in vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency (XSCID) results in sustained T cell reconstitution and sustained marking in myeloid and B cells for up to 4 years with no evidence of any serious adverse effects. The purpose of this study was to determine whether ex vivo γ-retroviral gene therapy of XSCID dogs results in a similar outcome. Eight of 12 XSCID dogs treated with an average of dose of 5.8 × 10(6) transduced CD34(+)  ...[more]

Similar Datasets

| S-EPMC4274995 | biostudies-literature
| S-EPMC5363493 | biostudies-literature
| S-EPMC2957288 | biostudies-literature
| S-EPMC6373733 | biostudies-literature
| S-EPMC5557273 | biostudies-literature
| S-EPMC295580 | biostudies-other
| S-EPMC7729079 | biostudies-literature
| S-EPMC7305219 | biostudies-literature
| S-EPMC5918176 | biostudies-literature
2023-01-02 | E-MTAB-12432 | biostudies-arrayexpress